secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0000899923-23-000083
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q3 revenue $191.9M, up 23% YoY; raises FY2023 guidance, introduces FY2024 guidance
--------------------------------------------------------------------------------

- Q3 revenue $191.9M (+23% YoY); GAAP EPS -$0.75, adjusted EPS -$0.03.
- Testing volume ex-SneakPeek +18% YoY; hereditary cancer +18%, prenatal +20%, GeneSight +19%.
- Raised FY2023 revenue guidance to $747-753M (prev $730-750M); introduced FY2024 guidance $815-835M.
- Settled Ravgen litigation for $12.75M plus contingent $21.25M; expanded credit facility to $115M.
- New UnitedHealthcare contract effective Jan 1, 2024 through 2027; appointed Sam Raha COO effective Dec 11.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000083/0000899923-23-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000083/mygn-20231106.htm
  HTML page:      https://secwatch.observer/filing/0000899923-23-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer